These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 18617263

  • 1. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B, Grzegorzewska M, Brański P, Domin H, Wierońska JM, Hess G, Smiałowska M.
    Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
    [Abstract] [Full Text] [Related]

  • 2. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, Tomisawa K.
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [Abstract] [Full Text] [Related]

  • 3. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.
    Harro J, Tõnissaar M, Eller M.
    Neuropeptides; 2001 Apr; 35(2):100-9. PubMed ID: 11384205
    [Abstract] [Full Text] [Related]

  • 4. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, Yan XX, Arneric SP, Robertson DW, Hartig PR, Grossman S, Trainor GL, Taub RA, Zaczek R, Gilligan PJ, McElroy JF.
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [Abstract] [Full Text] [Related]

  • 5. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
    McElroy JF, Ward KA, Zeller KL, Jones KW, Gilligan PJ, He L, Lelas S.
    Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat.
    Spina MG, Merlo-Pich E, Akwa Y, Balducci C, Basso AM, Zorrilla EP, Britton KT, Rivier J, Vale WW, Koob GF.
    Psychopharmacology (Berl); 2002 Mar; 160(2):113-21. PubMed ID: 11875628
    [Abstract] [Full Text] [Related]

  • 9. A role of noradrenergic receptors in anxiolytic-like effect of high CRF in the rat frontal cortex.
    Śmiałowska M, Zięba B, Domin H.
    Neuropeptides; 2021 Aug; 88():102162. PubMed ID: 34062382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The influence of CRF and alpha-helical CRF(9-41) on rat fear responses, c-Fos and CRF expression, and concentration of amino acids in brain structures.
    Skórzewska A, Bidziński A, Hamed A, Lehner M, Turzyńska D, Sobolewska A, Maciejak P, Szyndler J, Wisłowska-Stanek A, Płaźnik A.
    Horm Behav; 2008 Nov; 54(5):602-12. PubMed ID: 18601929
    [Abstract] [Full Text] [Related]

  • 12. Neonatal thyroxine treatment: changes in the number of corticotropin-releasing-factor (CRF) and neuropeptide Y (NPY) containing neurons and density of tyrosine hydroxylase positive fibers (TH) in the amygdala correlate with anxiety-related behavior of wistar rats.
    Yilmazer-Hanke DM, Hantsch M, Hanke J, Schulz C, Faber-Zuschratter H, Schwegler H.
    Neuroscience; 2004 Nov; 124(2):283-97. PubMed ID: 14980379
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats.
    Zarrindast MR, Solati J, Oryan S, Parivar K.
    Pharmacology; 2008 Nov; 82(4):276-84. PubMed ID: 18849647
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain.
    Nijsen M, Ongenae N, Meulemans A, Coulie B.
    Neurogastroenterol Motil; 2005 Jun; 17(3):423-32. PubMed ID: 15916630
    [Abstract] [Full Text] [Related]

  • 17. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF.
    Pelleymounter MA, Joppa M, Carmouche M, Cullen MJ, Brown B, Murphy B, Grigoriadis DE, Ling N, Foster AC.
    J Pharmacol Exp Ther; 2000 Jun; 293(3):799-806. PubMed ID: 10869378
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat.
    Gulec G, Isbil-Buyukcoskun N, Kahveci N.
    Neuropeptides; 2010 Aug; 44(4):285-91. PubMed ID: 20227110
    [Abstract] [Full Text] [Related]

  • 20. Corticotropin releasing factor enhances attentional function as assessed by the five-choice serial reaction time task in rats.
    Ohmura Y, Yamaguchi T, Futami Y, Togashi H, Izumi T, Matsumoto M, Yoshida T, Yoshioka M.
    Behav Brain Res; 2009 Mar 17; 198(2):429-33. PubMed ID: 19084036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.